Structural abnormalities include various types of translocations, inversions, deletions, duplications and isochromosomes. Structural abnormalities of the Y chromosome are estimated to affect less than 1% of the newborn male population and are particularly hazardous for male reproductive function. The objective of this study was to characterize a group of patients with structural abnormalities of the Y chromosome. All patients who visited our laboratory between 2007 and 2010 underwent cytogenetic investigations. Among these, we detected 26 patients with structural abnormalities of the Y chromosome. To confirm the structural Y chromosome alterations, we used special bandings, FISH and multiplex PCR to detect Y chromosome microdeletions. Of the 26 patients presented here, 11 had an isodicentric Y chromosome, 7 had an inversion, 3 had a translocation, 2 had a derivative, 2 had a Yqs and 1 had a deletion. Sixteen were diagnosed with azoospermia, 8 as normal fertile males and 1 as a man who was unable to donate semen due to mental retardation. One of the patients having 45,X/46,X,idic(Y) was reported to be phenotypically female with primary amenorrhea and without uterus. Deletions of the AZFbc region were correlated with the sperm concentration (p < 0.05), but no correlation with the levels of FSH, LH, testosterone, prolactin and estradiol were found. The present report shows that the precise identification of structural Y chromosome aberrations may be clinically important for genetic counseling and assisted reproductive technology treatment.

Keywords:
AZF region microdeletions, Infertility, Structural Y chromosome aberrations
1.
Aiello V, Astolfi N, Gruppioni R, Buldrini B, Prontera P, et al: Paracentric inversion of Yq and review of the literature. Genet Couns 18:379–382 (2007).
2.
Arnemann J, Schnittger S, Hinkel GK, Tolkendorf E, Schmidtke J, Hansmann I: A sterile male with 45,X0 and a Y;22 translocation. Hum Genet 87:134–138 (1991).
3.
Codina-Pascual M, Oliver-Bonet M, Navarro J, Starke H, Liehr T, et al: FISH characterization of a dicentric Yq (p11.32) isochromosome in an azoospermic male. Am J Med Genet A 127:302–306 (2004).
4.
Cui YX, Shi YC, Liu Q, Xia XY, Lu HY, et al: A case of agonadism associated with Y-chromosome rearrangement: cytogenetic and molecular studies. J Androl 30:650–654 (2009).
5.
Delobel B, Djlelati R, Gabriel-Robez O, Croquette MF, Rousseaux-Prevost R, et al: Y-autosome translocation and infertility: usefulness of molecular, cytogenetic and meiotic studies. Hum Genet 102:98–102 (1998).
6.
DesGroseilliers M, Fortin F, Lafreniere AM, Brochu P, Lemyre E, Lemieux N: Dynamic increase of a 45,X cell line in a patient with multicentric ring Y chromosomes. Cytogenet Genome Res 115:90–93 (2006).
7.
Disteche CM, Brown L, Saal H, Friedman C, Thuline HC, et al: Molecular detection of a translocation (Y;15) in a 45,X male. Hum Genet 74:372–377 (1986).
8.
Gardner RJ, Sutherland GR: Chromosome Abnormalities and Genetic Counseling. Sex chromosome translocations, pp 95–114 (Oxford University Press, Oxford 1996).
9.
Gekas J, Thepot F, Turleau C, Siffroi JP, Dadoune JP, et al: Chromosomal factors of infertility in candidate couples for ICSI: an equal risk of constitutional aberrations in women and men. Hum Reprod 16:82–90 (2001).
10.
Genest P, Bouchard M, Bouchard J: A satellited human Y chromosome: an evidence of autosome gonosome translocation. Can J Genet Cytol 9:589–595 (1967).
11.
Gimelli G, Giorda R, Beri S, Gimelli S, Zuffardi OA: 46,X,inv(Y) young woman with gonadal dysgenesis and gonadoblastoma: cytogenetics, molecular, and methylation studies. Am J Med Genet A 140:40–45 (2006).
12.
Hsu LY: Phenotype/karyotype correlations of Y chromosome aneuploidy with emphasis on structural aberrations in postnatally diagnosed cases. Am J Med Genet 53:108–140 (1994).
13.
Iourov IY, Vorsanova SG, Liehr T, Monakhov VV, Soloviev IV, Yurov YB: Dynamic mosaicism manifesting as loss, gain and rearrangement of an isodicentric Y chromosome in a male child with growth retardation and abnormal external genitalia. Cytogenet Genome Res 121:302–306 (2008).
14.
ISCN 2005: An International System for Cytogenetic Nomenclature (S. Karger, Basel 2005).
15.
ISCN 2009: An International System for Human Cytogenetic Nomenclature (S. Karger, Basel 2009).
16.
Krausz C, Quintana-Murci L, McElreavey K: Prognostic value of Y deletion analysis: what is the clinical prognostic value of Y chromosome microdeletion analysis? Hum Reprod 15:1431–1434 (2000).
17.
Lin YH, Chuang L, Lin YM, Lin YH, Teng YN, Kuo PL: Isochromosome of Yp in a man with Sertoli-cell-only syndrome. Fertil Steril 83:764–766 (2005).
18.
Liou JD, Ma YY, Gibson LH, Su H, Charest N, et al: Cytogenetic and molecular studies of a familial paracentric inversion of Y chromosome present in a patient with ambiguous genitalia. Am J Med Genet 70:134–137 (1997).
19.
Madan K: Paracentric inversions: a review. Hum Genet 96:503–515 (1995).
20.
Mademont-Soler I, Morales C, Madrigal I, Margarit E, Bruguera J, et al: Prenatal diagnosis of two different unbalanced forms of an inherited (Y;12) translocation. Am J Med Genet A 149A:2820–2823 (2009).
21.
Nielsen J, Rasmussen K: Y/autosomal translocations. Clin Genet 9:609–617 (1976).
22.
Pinton A, Raymond Letron I, Berland HM, Bonnet N, Calgaro A, et al: Meiotic studies in an azoospermic boar carrying a Y;14 translocation. Cytogenet Genome Res 120:106–111. (2008).
23.
Powell C: Sex chromosomes and sex abnormalities, in Gersen GL, Keagle MB (eds): The Principles of Clinical Cytogenetics, pp 229–258 (Humana Press, Totowa, NJ 1999).
24.
Robinson DO, Dalton P, Jacobs PA, Mosse K, Power MM, Crolla JA: A molecular and FISH analysis of structurally abnormal Y chromosomes in patients with Turner syndrome. J Med Genet 36:279–284 (1999).
25.
Schmid M, Haaf T, Solleder E, Schempp W, Leipoldt M, Heilbronner H: Satellited Y chromosomes: structure, origin, and clinical significance. Hum Genet 67:72–85 (1984).
26.
Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, et al: A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 346:240–244 (1990).
27.
Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, et al: The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 423:825–837 (2003).
28.
Tuck-Muller CM, Chen H, Martinez JE, Shen CC, Li S, et al: Isodicentric Y chromosome: cytogenetic, molecular and clinical studies and review of the literature. Hum Genet 96:119–129 (1995).
29.
Vogt PH, Edelmann A, Kirsch S, Henegariu O, Hirschmann P, et al: Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. Hum Mol Genet 5:933–943 (1996).
30.
World Health Organization: WHO Laboratory Manual for the Examination of Human Semen and Semen-Cervical Mucus Interaction, 4th ed. (Cambridge University Press, Cambridge 1999).
31.
Wyandt HE, Tonk VS: Atlas of Human Chromosome Heteromorphisms (Kluwer Academic Publishers, Dordrecht 2004).
32.
Yakut S, Ozturk S, Simsek M, Mendilcioglu II, Luleci G: The prenatal diagnosis of familial satellited Yq chromosomes. Turk J Med Sci 41:945–948 (2011).
33.
Zamani AG, Kutlu R, Durakbasi-Dursun HG, Gorkemli H, Acar A: Y chromosome microdeletions in Turkish infertile men. Indian J Hum Genet 12:66–71 (2006).
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.